Challenges with sirolimus experimental data to inform QSP model of post‐transplantation cyclophosphamide regimens
Clinical and Translational Science · 2024
DOI: 10.1111/cts.70014 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Ezhilpavai Mohanan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematologic Malignancies Translational Sciences, City of Hope, Duarte, California, USA. Hauptthemen laut MEDLINE: Sirolimus, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Cyclophosphamide. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIGMS NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Dose optimization of sirolimus may further improve outcomes in allogeneic hematopoietic cell transplant (HCT) patients receiving post‐transplantation cyclophosphamide (PTCy) to prevent graft‐versus‐host disease (GVHD). Sirolimus exposure–response association studies in HCT patients (i.e., the association of trough concentration with clinical outcomes) have been conflicting. Sirolimus has important effects on T‐cells, including conventional (Tcons) and regulatory T‐cells (Tregs), both of which have been implicated in the mechanisms by which PTCy prevents GVHD, but there is an absence of validated biomarkers of sirolimus effects on these cell subsets. Considering the paucity of existing biomarkers and the complexities of the immune system, we conducted a literature review to inform a quantitative systems pharmacology (QSP) model of GVHD. The published literature presented multiple challenges. The sirolimus pharmacokinetic models insufficiently describe sirolimus distribution to relevant physiological compartments. Despite multiple publications describing sirolimus effects on Tcons and Tregs in preclinical and human ex vivo models, consistent parameters relating sirolimus concentrations to circulating Tcons and Tregs could not be found. Each aspect presents a challenge in building a QSP model of sirolimus and its temporal effects on T‐cell subsets and GVHD prevention. To optimize GVHD prevention regimens, phase I studies and systematic studies of immunosuppressant concentration–effect association are needed for QSP modeling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematologic Malignancies Translational Sciences, City of Hope, Duarte, California, USA.
- Department of Pharmaceutical Sciences, University at Buffalo, SUNY, Buffalo, New York, USA.
- Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, California, USA.
- Department of Computational and Quantitative Medicine, City of Hope, Duarte, California, USA.
- Department of Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, California, USA.
- Department of Cancer Biology and Molecular Medicine, City of Hope, Duarte, California, USA.
ORCID-Profile: Ezhilpavai Mohanan, Guofang Shen, Suping Ren, Hsuan-Hao Fan, Kao Tang Ying Moua, Aleksandra Karolak, Russell C Rockne, Ryotaro Nakamura, David A Horne, Christopher G Kanakry, Donald E Mager, Jeannine S McCune
Förderung
- NIGMS NIH HHS
- NCI NIH HHS
Zitieren
APA
Mohanan, E., Shen, G., Ren, S., Fan, H. H., Moua, K. T. Y., Karolak, A., Rockne, R. C., Nakamura, R., Horne, D. A., Kanakry, C. G., Mager, D. E., & McCune, J. S. (2024). Challenges with sirolimus experimental data to inform QSP model of post‐transplantation cyclophosphamide regimens. Clinical and Translational Science. https://doi.org/10.1111/cts.70014
Vancouver
Mohanan E, Shen G, Ren S, Fan HH, Moua KTY, Karolak A, et al. Challenges with sirolimus experimental data to inform QSP model of post‐transplantation cyclophosphamide regimens. Clinical and Translational Science. 2024. doi:10.1111/cts.70014
BibTeX
@article{Mohanan2024,
author = {Mohanan, Ezhilpavai and Shen, Guofang and Ren, Suping and Fan, Hsuan-Hao and Moua, Kao Tang Ying and Karolak, Aleksandra and Rockne, Russell C and Nakamura, Ryotaro and Horne, David A and Kanakry, Christopher G and Mager, Donald E and McCune, Jeannine S},
title = {Challenges with sirolimus experimental data to inform QSP model of post‐transplantation cyclophosphamide regimens},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.70014}
}
EUVIMED